Applications Are Open: 2026 Power Player Awards
Nominate yourself (or someone who deserves it).
The focus of the partnership has shifted to whether solutions targeting the microbiome can deliver benefits alongside GLP-1-based medicines
Nestle believes the drugs are also creating a new market for products designed to address the side effects of rapid weight loss
Gyms are evolving to keep up with climbing GLP-1 adoption, offering muscle-preservation workouts, telehealth partnerships and integrated wellness services
More than 25% of GLP-1 users in the U.K. reported increasing fitness spending after starting treatment. Those results are promising, but other data shows it's far from a given that weight-loss drugs will prove to be a net benefit for the industry
Fitbit data from 750 adults found that daily movement and exercise levels declined after people started taking GLP-1 weight-loss drugs.
Early clinical trial results show that apitegromab dramatically reduced lean mass loss in people taking tirzepatide, the main ingredient in Mounjaro.
While improved health awareness and aging populations have also boosted whey prices, the GLP-1 trend is the key factor behind demand.
Despite the ubiquity of GLP-1s, only a small percentage of people are currently using them, according to a new report from Reach3 Insights.
GLP-1s are more accessible than ever, with everyone from gyms and telehealth companies offering prescriptions to weight loss medication. Support ranges the gamut: some online platforms act as an insurance concierge and offer regular virtual check-ins with a health professional, while others provide seamless access through a self-led program.
The top fitness industry trade organizations in the U.S., U.K. and Australia, among others, say GLP‑1s must be embedded in integrated care models that prioritize exercise and nutrition.
Sign Up to Our Newsletter
